i-spy 2: durvalumab in combination with olaparib and paclitaxel in high-risk her2 negative stage...
Published 3 years ago • 48 plays • Length 9:17Download video MP4
Download video MP3
Similar videos
-
1:22
dr. pusztai on rationale for the i-spy 2 trial with durvalumab/olaparib combo in her2- breast cancer
-
4:47
phase iii study of veliparib with carboplatin and paclitaxel in her2-negative advanced/metastati...
-
0:46
dr. esserman discusses the i-spy 2 trial
-
1:56
dr. esserman on the elements of the i-spy 2 trial in breast cancer
-
1:22
olaparib and paclitaxel for 2nd line gastric cancer therapy
-
3:02
trial investigates multiparametric prognostic score in early hr /her2- breast cancer
-
1:25
meredith buxton on i-spy 2 trial for her2 breast cancer
-
8:25
study of nab-paclitaxel with pembrolizumab for patients with hr /her2- breast cancer
-
0:58
dr. esserman discusses the i-spy 2 trial in breast cancer
-
2:59
brocade3: veliparib with carboplatin/paclitaxel in her2-/brca advanced breast cancer
-
2:10
dr aditya bardia on how combining sacituzumab govitecan, talazoparib amplifies treatment response
-
1:06
dr. esserman on the basis for the i-spy 2 trial in breast cancer
-
1:33
ongoing trial of abemaciclib and pembrolizumab in hr /her2-negative breast cancer
-
1:52
rationale for combining olaparib with neratinib in her2 uterine serous carcinoma
-
3:04
advances in parp inhibitor use for metastatic breast cancer
-
4:45
giredestrant plus palbociclib vs anastrozole plus palbociclib for post-menopausal, her2-negative...
-
1:46
combination of veliparib and chemotherapy in brca-positive breast cancer
-
1:20
phase ii adapt trial in patients with her2 and hr early breast cancer
-
6:43
olaparib and investigational pi3k inhibitor bkm120 combination active against ovarian